Perindopril-based blood pressure lowering in individuals with cerebrovascular disease: Consistency of benefits by age, sex and region

Journal of Hypertension

Volumn 22, Issue 3, 2004, Pages 653-659

  Rodgers, Anthony ^a   Chapman, Neil ^b   Woodward, Mark ^b   Liu, Li Sheng ^c   Colman, Sam ^b   Lee, Arier ^a   Chalmers, John ^b   MacMahon, Stephen ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF SYDNEY   (Australia)

^c FUWAI HOSPITAL   (China)

Author keywords

Age; Asia; Blood pressure; Cardiovascular events; Indapamide; Perlndopril; Randomized controlled trial; Sex; Stroke

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INDAPAMIDE; PERINDOPRIL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; HAZARD ASSESSMENT; HUMAN; HYPOTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SIDE EFFECT; STANDARD; STROKE; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE;

EID: 1642365732     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200403000-00030     Document Type: Article

References (29)

1. World Health Organization. World Health Report 2002. Reducing risks, promoting healthy life. Geneva: WHO; 2002.
2. Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003; 21: 707-716.
3. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
4. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.
5. PROGRESS Management Committee. Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS. J Hypertens 1996; 14(suppl 2):S41-S46.
6. PROGRESS Management Committee. PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Characteristics of the study population at baseline. J Hypertens 1999; 17:1647-1655.
7. MacMahon S, Rodgers A. The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. J Clin Exp Hypertens 1993; 15:967-978.
8. Gueyffier F, Bulpitt C, Boissel J-P, Schron E, Ekbom T, Fagard R, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet 1999; 353:793-796.
9. Rodgers A, MacMahon S, Gamble G, Slattery J, Sandercock P, Warlow C, et al. Blood pressure and risk of stroke in patients with cerebrovascular disease. BMJ 1996; 313:147.
10. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part I, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765-774.
11. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 355:1955-1964.
12. Hunt D, Young P, Simes J, Hague W, Mann S, Owensby D, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Int Med 2001; 134:931-940.
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
14. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308:367-373.
15. Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Int Med 1997; 126:761-767.
16. Liu L, Gong L, Wang JG. Blood pressure lowering in patients with cerebrovascular disease: results of the randomized post-stroke antihypertensive treatment study (PATS) [Abstract]. J Am Coll Cardiol 1998; 31(suppl A):211A.
17. 7 Liu L, Wang JG, Gong L, Liu G, Staessen JA, for the Systolic Hypertension in China (Syst-China) Collaborative Group. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens 1998; 16:1823-1829.
18. Hamet P, Gong L. Antihypertensive therapy debate: contribution from the Shanghai Trial Of Nifedipine in the Elderly (STONE). J Hypertens 1996; 14(suppl 4):S9-S14.
19. Gong L, Zhang W, Zhu Y, Zhu J, Kong D, Page V, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14:1237-1245.
20. Feldmann E, Daneault N, Kwan E, Ho KJ, Pessin MS, Langenberg P, et al. Chinese-white differences in the distribution of occlusive cerebrovascular disease. Neurology 1990; 40:1541-1545.
21. Eastern Stroke and Coronary Heart Disease Collaborative Group. Blood pressure, cholesterol and stroke in eastern Asia. Lancet 1998; 352:1801-1807.
22. Reed D, Jacobs DR, Hayashi T, Konishi M, Nelson J, Iso H, et al. A comparison of lesions in small intracerebral arteries among Japanese men in Hawaii and Japan. Stroke 1994; 25:60-65.
23. 2:3 Shimamoto T, Komachi Y, Inada H, Doi M, Iso H, Sato S, et al. Trends for coronary heart disease and stroke and their risk factors in Japan. Circulation 1989; 79:503-515.
24. Collins R, Peto R, Gray R, Parish S. Large-scale randomized evidence: trials and overviews. In: Weatherall DJ, Ledingham JGG, Warrell DA (editors): Oxford textbook of medicine. 3rd ed. Oxford: Oxford University Press; 1996, pp. 21-32.
25. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991; 266:93-98.
26. Glasziou PP, Irwig LM. An evidence based approach to individualising treatment. BMJ 1995; 311:1356-1359.
27. Murray CJL, Lopez AD. Global health statistics: a compendium of incidence, prevalence and mortality estimates for over 200 conditions. Cambridge: Harvard University Press; 1996.
28. Bots ML, van der Wilk EC, Koudstaal PJ, Hofman A, Grobbee DE. Transient neurological attacks in the general population. Prevalence, risk factors, and clinical relevance. Stroke 1997; 28:768-773.
29. Brown RDJ, Petty GW, O'Fallon WM, Wiebers DO, Whisnant JP. Incidence of transient ischemic attack in Rochester, Minnesota, 1985-1989. Stroke 1998; 29:2109-2113.